Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
作者信息
Willmann Stefan, Zhang Liping, Mayer Hannah, Siegmund Hans-Ulrich, Tanigawa Takahiko, Kaneko Masato, Peters Gary, Weitz Jeffrey I, Berkowitz Scott D, Burghaus Rolf
机构信息
Clinical Pharmacometrics, Bayer AG, Wuppertal, Germany.
Global Clinical Pharmacology, Janssen Research & Development LLC, Raritan, NJ.
出版信息
Blood Adv. 2018 Nov 27;2(22):3193-3195. doi: 10.1182/bloodadvances.2018027078.
Abstract
摘要
相似文献
1
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Blood Adv. 2018 Nov 27;2(22):3193-3195. doi: 10.1182/bloodadvances.2018027078.
2
Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis.
J Cardiovasc Med (Hagerstown). 2020 Aug;21(8):570-576. doi: 10.2459/JCM.0000000000001041.
3
Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Acta Cardiol. 2016 Jun;71(3):349-57. doi: 10.2143/AC.71.3.3152095.
4
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Curr Opin Cardiol. 2010 Jul;25(4):312-20. doi: 10.1097/HCO.0b013e32833a524f.
5
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
J Neurol. 2020 Jul;267(7):2007-2012. doi: 10.1007/s00415-020-09795-3. Epub 2020 Mar 23.
6
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
J Thromb Thrombolysis. 2019 Oct;48(3):366-372. doi: 10.1007/s11239-019-01898-7.
7
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Vasa. 2016;45(4):293-8. doi: 10.1024/0301-1526/a000540.
8
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Cardiovasc Drugs Ther. 2013 Feb;27(1):23-35. doi: 10.1007/s10557-012-6426-9.
9
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.
Nat Rev Cardiol. 2012 Feb 28;9(7):385-91. doi: 10.1038/nrcardio.2012.19.
10
Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
Ther Adv Cardiovasc Dis. 2016 Feb;10(1):37-49. doi: 10.1177/1753944715605011. Epub 2015 Sep 16.
本文引用的文献
1
Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation.
TH Open. 2018 May 29;2(2):e190-e201. doi: 10.1055/s-0038-1649507. eCollection 2018 Apr.
2
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15.
3
Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Blood Adv. 2018 May 22;2(10):1066-1075. doi: 10.1182/bloodadvances.2017013805.
4
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.
CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):309-320. doi: 10.1002/psp4.12288. Epub 2018 Apr 16.
5
Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
J Thromb Haemost. 2017 Oct;15(10):2017-2028. doi: 10.1111/jth.13801. Epub 2017 Sep 14.
6
Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Int J Lab Hematol. 2016 Oct;38(5):505-13. doi: 10.1111/ijlh.12528. Epub 2016 Jun 6.
7
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
J Thromb Haemost. 2014 Nov;12(11):1810-5. doi: 10.1111/jth.12720. Epub 2014 Oct 12.
8
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
J Clin Pharmacol. 2014 Aug;54(8):917-27. doi: 10.1002/jcph.288. Epub 2014 Mar 26.
9
Edoxaban versus warfarin in patients with atrial fibrillation.
N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.
10
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.
Clin Pharmacokinet. 2014 Jan;53(1):1-16. doi: 10.1007/s40262-013-0100-7.
Zotero 插件